AMPH logo

Amphastar Pharmaceuticals, Inc. Stock Price

NasdaqGS:AMPH Community·US$1.1b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 43 Fair Values set on narratives written by author

AMPH Share Price Performance

US$23.63
-25.66 (-52.06%)
37.8% undervalued intrinsic discount
US$38.00
Fair Value
US$23.63
-25.66 (-52.06%)
37.8% undervalued intrinsic discount
US$38.00
Fair Value
Price US$23.63
AnalystHighTarget US$38.00
AnalystConsensusTarget US$31.89
AnalystLowTarget US$27.08

AMPH Community Narratives

AnalystHighTarget·
Fair Value US$38 31.6% undervalued intrinsic discount

Aging Population Will Expand Markets Despite Intense Rivalry

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value US$32 18.8% undervalued intrinsic discount

Intensified Competition Will Erode Margins For Generic Pharmaceuticals

0users have liked this narrative
0users have commented on this narrative
30users have followed this narrative
AnalystLowTarget·
Fair Value US$25 3.9% overvalued intrinsic discount

Intensifying Pricing Pressure Will Erode Margins And Revenue

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent AMPH News & Updates

After Protracted Sell-Off, Amphastar Looks Like A Value Pick

Sep 23

Earnings Working Against Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Share Price

Jul 01
Earnings Working Against Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Share Price

Amphastar Pharmaceuticals, Inc. Key Details

US$722.7m

Revenue

US$362.3m

Cost of Revenue

US$360.3m

Gross Profit

US$225.6m

Other Expenses

US$134.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
2.90
Gross Margin
49.86%
Net Profit Margin
18.64%
Debt/Equity Ratio
80.3%

Amphastar Pharmaceuticals, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Very undervalued with mediocre balance sheet.

1 Risk
4 Rewards

About AMPH

Founded
1996
Employees
2028
CEO
Yongfeng Zhang
WebsiteView website
www.amphastar.com

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 5.1%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.7%, driven by a pullback of 2.5% in the Information Technology sector. As for the longer term, the market has actually risen by 13% in the last year. Earnings are forecast to grow by 15% annually. Market details ›